How Druggable Is Protein Kinase CK2?

被引:55
|
作者
Cozza, Giorgio [1 ]
Bortolato, Andrea [1 ]
Moro, Stefano [1 ]
机构
[1] Univ Padua, Dept Pharmaceut Sci, MMS, I-35131 Padua, Italy
关键词
protein kinase CK2; REGULATORY BETA-SUBUNIT; STRUCTURE-BASED DESIGN; ANGIOTENSIN-CONVERTING ENZYME; COMPETITIVE INHIBITOR EMODIN; DNA TOPOISOMERASE-II; RIBOSOMAL-P PROTEINS; BREAST-CANCER CELLS; CASEIN KINASE-2; ALPHA-SUBUNIT; CATALYTIC-SUBUNIT;
D O I
10.1002/med.20164
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
CK2 is a pleiotropic, ubiquitous, and constitutively active protein kinase (PK), with both cytosolic and nuclear localization in most mammalian cells. The holoenzyme is generally composed of two catalytic (alpha and/or alpha') and two regulatory (beta) subunits, but the free alpha/alpha' subunits are catalytically active by themselves and can be present in cells under some circumstances. CK2 catalyzes the phosphorylation of more than 300 substrates characterized by multiple acidic residues surrounding the phosphor-acceptor amino acid, and, consequently, it plays a key role in several physiological and pathological processes. But how can one kinase orchestrate all these tasks faithfully? How is it possible that one kinase can, despite all pleiotropic characteristics of PKs in general, be involved in so many different biochemical events? Is CK2 a druggable target? Several questions are still to be clearly answered, and this review is an occasion for a fruitful discussion. (C) 2009 Wiley Periodicals, Inc. Med Res Rev, 30, No. 3, 419-462, 2010
引用
收藏
页码:419 / 462
页数:44
相关论文
共 50 条
  • [41] Bovine prion protein as a modulator of protein kinase CK2
    Meggio, F
    Negro, A
    Sarno, S
    Ruzzene, M
    Bertoli, A
    Sorgato, MC
    Pinna, LA
    BIOCHEMICAL JOURNAL, 2000, 352 : 191 - 196
  • [42] Protein kinase CK2 inhibition as a pharmacological strategy
    Borgo, Christian
    Ruzzene, Maria
    ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY, VOL 124: PROTEIN KINASES IN DRUG DISCOVERY, 2021, 124 : 23 - 46
  • [43] Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2
    Gianoncelli, Alessandra
    Cozza, Giorgio
    Orzeszko, Andrzej
    Meggio, Flavio
    Kazimierczuk, Zygmunt
    Pinna, Lorenzo A.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (20) : 7281 - 7289
  • [44] Protein kinase CK2 in mammary gland tumorigenesis
    Landesman-Bollag, E
    Romieu-Mourez, R
    Song, DH
    Sonenshein, GE
    Cardiff, RD
    Seldin, DC
    ONCOGENE, 2001, 20 (25) : 3247 - 3257
  • [45] The selectivity of inhibitors of protein kinase CK2: an update
    Pagano, Mario A.
    Bain, Jenny
    Kazimierczuk, Zygmunt
    Sarno, Stefania
    Ruzzene, Maria
    Di Maira, Giovanni
    Elliott, Matthew
    Orzeszko, Andrzej
    Cozza, Giorgio
    Meggio, Flavio
    Pinna, Lorenzo A.
    BIOCHEMICAL JOURNAL, 2008, 415 (353-365) : 353 - 365
  • [46] Identification of proteins that associate with protein kinase CK2
    Dongxia Li
    Grazyna Dobrowolska
    Edwin G. Krebs
    Molecular and Cellular Biochemistry, 1999, 191 : 223 - 228
  • [47] Validation of protein kinase CK2 as oncological target
    Seeber, S
    Issinger, OG
    Holm, T
    Kristensen, LP
    Guerra, B
    APOPTOSIS, 2005, 10 (04) : 875 - 885
  • [48] Protein kinase CK2 inhibitors: a patent review
    Cozza, Giorgio
    Pinna, Lorenzo A.
    Moro, Stefano
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (09) : 1081 - 1097
  • [49] Protein kinase CK2: from structures to insights
    K. Niefind
    J. Raaf
    O.-G. Issinger
    Cellular and Molecular Life Sciences, 2009, 66 : 3535 - 3536
  • [50] A Journey through the Cytoskeleton with Protein Kinase CK2
    D'Amore, Claudio
    Salizzato, Valentina
    Borgo, Christian
    Cesaro, Luca
    Pinna, Lorenzo A.
    Salvi, Mauro
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2019, 20 (06) : 547 - 562